AstraZeneca to Invest $2 Bn in Maryland Biologics Manufacturing Expansion

The investment will nearly double AstraZeneca’s biologics manufacturing capacity at its Frederick site while establishing a new clinical-supply facility in Gaithersburg, supporting around 2,600 jobs across both locations.

AstraZeneca plans a $2 billion investment to expand its biologics manufacturing operations in Maryland, United States, as part of a strategy to strengthen production and research capacity across key therapeutic areas.

The expansion covers a significant scale-up of commercial biologics manufacturing at Frederick and the creation of a new clinical-supply facility in Gaithersburg, together supporting around 2,600 jobs.

The Frederick facility enters its next phase with a near doubling of commercial biologics capacity, enabling increased output across AstraZeneca’s cancer, autoimmune, respiratory and rare-disease portfolios.

In parallel, the Gaithersburg site is set up as a dedicated clinical-supply manufacturing facility, focused on supporting pipeline molecules and late-stage development programmes, and is expected to be operational by 2029 with additional roles alongside retained jobs in the region.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said, “Today marks a landmark moment for Maryland and American patients. As the state’s largest biopharmaceutical employer, we are deepening our long-standing commitment to Maryland - supporting 2,600 jobs, catalyzing economic growth, and bringing our extensive rare-disease portfolio on-shore for the first time. This investment strengthens the resilience of the US medicines supply chain and accelerates access to transformative therapies for patients across America and around the world.”

From the state’s perspective, Wes Moore, Governor of Maryland, said the investment underscores Maryland’s position as a global life-sciences hub and is expected to create hundreds of good-paying jobs while reinforcing the security of the medicines supply chain.

The manufacturing expansion incorporates advanced technologies such as artificial intelligence, automation and data analytics across production lines and quality systems.

According to the drugmaker, the new and upgraded facilities are being designed to meet high environmental standards, aligning with its broader approach to sustainable and technology-enabled biopharmaceutical manufacturing.

Stay tuned for more such updates on Digital Health News